How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

378 results for

Tiagabine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Tiagabine treatment in kainic acid induced cerebellar lesion of dystonia rat model (PubMed)

Tiagabine treatment in kainic acid induced cerebellar lesion of dystonia rat model Dystonia is a neurological disorder characterized by excessive involuntary muscle contractions that lead to twisting movements. The exaggerated movements have been studied and have implicated basal ganglia as the point of origin. In more recent studies, the cerebellum has also been identified as the possible target of dystonia, in the search for alternative treatments. Tiagabine is a selective GABA transporter (...) inhibitor, which blocks the reuptake and recycling of GABA. The study of GABAergic drugs as an alternative treatment for cerebellar induced dystonia has not been reported. In our study, tiagabine was i.p. injected into kainic acid induced, cerebellar dystonic adult rats, and the effects were compared with non-tiagabine injected and sham-operated groups. Beam walking apparatus, telemetric electromyography (EMG) recording, and histological verification were performed to confirm dystonic symptoms

Full Text available with Trip Pro

2016 EXCLI journal

2. Tiagabine for acute affective episodes in bipolar disorder. (PubMed)

Tiagabine for acute affective episodes in bipolar disorder. Bipolar disorder is a common recurrent illness with high levels of chronicity. Treatment resistance persists despite the use of established medications, such as lithium and valproate. New medications are required for the treatment of refractory cases. Some open-label reports have suggested that the anticonvulsant tiagabine may be efficacious in bipolar disorder. There is a need to clarify the evidence available, in the form (...) of randomised controlled trials, for its use in the treatment of acute affective episodes in bipolar disorder.To review the evidence for the efficacy and acceptability of tiagabine in the treatment of acute mood episodes in bipolar disorder.In this update, we searched the Cochrane Depression, Anxiety and Neurosis Group's Specialised Register (CCDANCTR-Studies and CCDANCTR-References) to October 2012. This register contains relevant randomised controlled trials from: The Cochrane Library (all years), EMBASE

2012 Cochrane

3. Tiagabine in the maintenance treatment of bipolar disorder. (PubMed)

Tiagabine in the maintenance treatment of bipolar disorder. Tiagabine, an anticonvulsant, has been reported to have efficacy in prophylactic treatment of bipolar disorder in case reports and in case series.To assess the efficacy and acceptability of tiagabine, relative to placebo, and other agents in the prevention or attenuation, or both, of episodes of bipolar disorder in adults. The efficacy and acceptability of tiagabine were considered in terms of mood symptoms, mortality, general health (...) disorder were examined. Authors, other experts in the field and pharmaceutical companies were contacted for knowledge of suitable published or unpublished trials. Specialist journals and conference proceedings were handsearched.Randomised controlled trials of tiagabine versus placebo, alternative mood stabilisers or antipsychotics, for the maintenance treatment of bipolar disorder in adults, male and female, aged 18 to 74 years.Data were to be extracted from the original reports of included studies

2011 Cochrane

4. Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation (PubMed)

Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation The frequency of visual gamma oscillations is determined by both the neuronal excitation-inhibition balance and the time constants of GABAergic processes. The gamma peak frequency has been linked to sensory processing, cognitive function, cortical structure, and may have a genetic contribution. To disentangle the intricate relationship among these factors (...) , accurate and reliable estimates of peak frequency are required. Here, a bootstrapping approach that provides estimates of peak frequency reliability, thereby increasing the robustness of the inferences made on this parameter was developed. The method using both simulated data and real data from two previous pharmacological MEG studies of visual gamma with alcohol and tiagabine was validated. In particular, the study by Muthukumaraswamy et al. [] (Neuropsychopharmacology 38(6):1105-1112), in which

Full Text available with Trip Pro

2016 Human brain mapping

5. Tiagabine

Tiagabine Tiagabine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Tiagabine Tiagabine Aka: Tiagabine , Gabitril II. Class (...) from a Bing search on the term "Tiagabine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications tiagabine (on 7/13/2016 at ) TIAGABINE HCL 2 MG TABLET Generic $5.10 each TIAGABINE HCL 4 MG TABLET Generic $4.81 each gabitril (on 1/1/2017 at ) GABITRIL 12 MG TABLET $9.63 each GABITRIL 16 MG TABLET $12.87 each GABITRIL 4 MG TABLET Generic $4.81 each FPNotebook does not benefit financially from showing

2018 FP Notebook

6. Effects of Tiagabine on Slow Wave Sleep and Arousal Threshold in Patients With Obstructive Sleep Apnea (PubMed)

Effects of Tiagabine on Slow Wave Sleep and Arousal Threshold in Patients With Obstructive Sleep Apnea Obstructive sleep apnea (OSA) severity is markedly reduced during slow-wave sleep (SWS) even in patients with a severe disease. The reason for this improvement is uncertain but likely relates to non-anatomical factors (i.e. reduced arousability, chemosensitivity, and increased dilator muscle activity). The anticonvulsant tiagabine produces a dose-dependent increase in SWS in subjects without (...) OSA. This study aimed to test the hypothesis that tiagabine would reduce OSA severity by raising the overall arousal threshold during sleep.After a baseline physiology night to assess patients' OSA phenotypic traits, a placebo-controlled, double-blind, crossover trial of tiagabine 12 mg administered before sleep was performed in 14 OSA patients. Under each condition, we assessed the effects on sleep and OSA severity using standard clinical polysomnography.Tiagabine increased slow-wave activity

Full Text available with Trip Pro

2016 Sleep

7. Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea

Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tiagabine to Enhance Slow (...) by (Responsible Party): David Andrew Wellman, Brigham and Women's Hospital Study Details Study Description Go to Brief Summary: Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investigators test the idea that the medication called "tiagabine" improves slow wave sleep

2015 Clinical Trials

8. Tiagabine add-on for drug-resistant partial epilepsy. (PubMed)

Tiagabine add-on for drug-resistant partial epilepsy. Epilepsy is a common neurological condition that affects almost 0.5% to 1% of the population. Nearly 30% of people with epilepsy are resistant to currently available drugs. Tiagabine is one of the newer antiepileptic drugs; its effects as an adjunct (add-on) to standard drugs are assessed in this review.To evaluate the effects of add-on treatment with tiagabine on seizures, adverse effects, cognition and quality of life for people with drug (...) -resistant localisation-related seizures.This is an updated version of the original Cochrane review published in 2012 (Issue 5). We searched the Cochrane Epilepsy Group Specialised Register (November 2013), the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 10) and MEDLINE (1946 to November 2013). No language restrictions were imposed. We also contacted the manufacturers of tiagabine and experts in the field to seek any ongoing or unpublished studies.Randomised placebo-controlled

Full Text available with Trip Pro

2014 Cochrane database of systematic reviews (Online)

9. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) , oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text Aetiology New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Statistics from Altmetric.com Question Question Is new use of anticonvulsants associated with an increased risk of suicidal acts or violent death? People 297 620 people aged over 15 years of age who began taking

2010 Evidence-Based Mental Health

10. Classification of High-Activity Tiagabine Analogs by Binary QSAR Modeling (PubMed)

Classification of High-Activity Tiagabine Analogs by Binary QSAR Modeling 23956803 2018 11 13 1868-1743 32 5-6 2013 Jun Molecular informatics Mol Inform Classification of High-Activity Tiagabine Analogs by Binary QSAR Modeling. 415-419 Jurik Andreas A University of Vienna, Department of Medicinal Chemistry Althanstraße 14, A-1090 Vienna, Austria phone/fax: +431-4277-55110/-9551. Reicherstorfer Regina R Zdrazil Barbara B Ecker Gerhard F GF eng F 3502 Austrian Science Fund FWF Austria Journal (...) Article 2013 05 15 Germany Mol Inform 101529315 1868-1743 Binary QSAR GABA uptake inhibitors GAT-1 Tiagabine 2013 02 12 2013 03 28 2013 8 20 6 0 2013 8 21 6 0 2013 8 21 6 1 ppublish 23956803 10.1002/minf.201300020 PMC3743161 Curr Top Med Chem. 2006;6(17):1861-82 17017962 J Med Chem. 2001 Jun 21;44(13):2152-63 11405652 Neurochem Int. 2006 May-Jun;48(6-7):637-42 16517017 Bioorg Med Chem Lett. 2006 Jan 1;16(1):225-7 16246548 Eur J Pharmacol. 1991 Apr 24;196 (3):257-66 1832636 Neuropsychiatr Dis Treat

Full Text available with Trip Pro

2013 Molecular Informatics

11. Tiagabine in clinical practice: effects on seizure control and behavior.

Tiagabine in clinical practice: effects on seizure control and behavior. Preapproval randomized controlled trials of antiepileptic drugs provide data in limited patient groups. We assessed the side effect and seizure reduction profile of tiagabine (TGB) in typical clinical practice.Investigators recorded adverse effect (AE), seizure, and assessment-of-benefit data prospectively in sequential patients treated open label with TGB.Two hundred ninety-two patients (39 children) were enrolled

2013 Epilepsy & behavior : E&B

12. Slow Wave Sleep Induced by GABA Agonist Tiagabine Fails to Benefit Memory Consolidation. (PubMed)

Slow Wave Sleep Induced by GABA Agonist Tiagabine Fails to Benefit Memory Consolidation. Slow wave sleep (SWS) plays a pivotal role in consolidating memories. Tiagabine has been shown to increase SWS in favor of REM sleep without impacting subjective sleep. However, it is unknown whether this effect is paralleled by an improved sleep-dependent consolidation of memory.This double-blind within-subject crossover study tested sensitivity of overnight retention of declarative neutral and emotional (...) materials (word pairs, pictures) as well as a procedural memory task (sequence finger tapping) to oral administration of placebo or 10 mg tiagabine (at 22:30).Fourteen healthy young men aged 21.9 years (range 18-28 years).Tiagabine significantly increased the time spent in SWS and decreased REM sleep compared to placebo. Tiagabine also enhanced slow wave activity (0.5-4.0 Hz) and density of < 1 Hz slow oscillations during NREM sleep. Fast (12-15 Hz) and slow (9-12 Hz) spindle activity, in particular

Full Text available with Trip Pro

2013 Sleep

13. Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults. (PubMed)

Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults. 19617947 2012 08 23 2018 11 13 1523-5998 11 3 2009 Primary care companion to the Journal of clinical psychiatry Prim Care Companion J Clin Psychiatry Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults. 123 Urbano Maria R MR Spiegel David R DR Laguerta Nena N Shrader Catherine J CJ Rowe Daniel F DF Hategan Liana F LF eng Journal Article United

2012 Primary Care Companion to the Journal of Clinical Psychiatry

14. Tiagabine

Tiagabine Tiagabine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Tiagabine Tiagabine Aka: Tiagabine , Gabitril II. Class (...) from a Bing search on the term "Tiagabine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications tiagabine (on 7/13/2016 at ) TIAGABINE HCL 2 MG TABLET Generic $5.10 each TIAGABINE HCL 4 MG TABLET Generic $4.81 each gabitril (on 1/1/2017 at ) GABITRIL 12 MG TABLET $9.63 each GABITRIL 16 MG TABLET $12.87 each GABITRIL 4 MG TABLET Generic $4.81 each FPNotebook does not benefit financially from showing

2015 FP Notebook

15. Behavioral Effects of Tiagabine and Cannabis

Behavioral Effects of Tiagabine and Cannabis Behavioral Effects of Pregabalin and Cannabis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Behavioral Effects of Pregabalin and Cannabis The safety

2012 Clinical Trials

16. Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. (PubMed)

Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. Anticonvulsants, notably those which modulate GABA activity, have shown efficacy in reducing aggressive behavior. Previously, we found dose-related decreases in human aggressive responding following acute tiagabine administration. Here, we examined the effects of chronic tiagabine over a 5-week period. Twelve individuals at increased risk for aggressive (...) and violent behavior (currently on parole/probation with personality and/or substance use disorders) were randomly assigned to placebo (n = 6) or an escalating dose sequence of placebo, 4 mg, 8 mg, 12 mg, placebo (n = 6). Data were analyzed using both frequentist and Bayesian mixed models, evaluating aggressive behavior as a function of time, dose condition, and their interaction. For aggressive responding, there was a significant interaction of drug condition and time. Aggression in the tiagabine

Full Text available with Trip Pro

2012 Journal of psychopharmacology (Oxford, England)

17. Tiagabine add-on for drug-resistant partial epilepsy. (PubMed)

Tiagabine add-on for drug-resistant partial epilepsy. Epilepsy is a common neurological condition, affecting almost 0.5 to 1% of the population. Nearly 30% of people with epilepsy are resistant to currently available drugs. Tiagabine is one of the newer antiepileptic drugs and its effects as an adjunct (add-on) to standard drugs are assessed in this review.To evaluate the effects of add-on treatment with tiagabine upon seizures, adverse effects, cognition and quality of life for people (...) with drug-resistant localisation related seizures.This is an updated version of the original Cochrane review published in issue 10, 2010. We searched the Cochrane Epilepsy Group's Specialised Register (December 2011), the Cochrane Central Register of Controlled Trials (CENTRAL, issue 4, 2011 of The Cochrane Library), and MEDLINE (1948 to November 2011). No language restrictions were imposed. We also contacted the manufacturers of tiagabine and experts in the field to seek any ongoing or unpublished

Full Text available with Trip Pro

2012 Cochrane database of systematic reviews (Online)

18. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. (PubMed)

Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. By reducing neuronal excitability through selective binding to the α(2)δ subunit of voltage-dependent calcium channels, pregabalin effectively treats epilepsy, chronic pain, and anxiety disorders. To evaluate if pregabalin coadministration affects pharmacokinetics of other antiepileptic drugs, population pharmacokinetic analyses using NONMEM software (...) were performed on data from three epilepsy trials involving seven antiepileptic drugs with pregabalin as add-on therapy. Results demonstrated that pregabalin did not alter the steady-state plasma concentrations of carbamazepine, lamotrigine, phenobarbital, phenytoin, tiagabine, topiramate, and valproate. Furthermore, the small percent change in the population estimate of antiepileptic drug plasma clearance values (-2% to +7%) suggests that pregabalin coadministration exerted no significant effect

Full Text available with Trip Pro

2011 Epilepsia

19. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. (PubMed)

An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we (...) aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global

2010 Journal of psychopharmacology (Oxford, England)

20. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies (PubMed)

Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies The objective of these studies was to evaluate the efficacy and tolerability of tiagabine, a selective gamma-aminobutyric acid reuptake inhibitor, in adult patients with generalized anxiety disorder (GAD). Patients with a diagnosis of GAD were enrolled in 1 of 3 randomized, placebo-controlled, 10-week studies. In each study, tiagabine was taken twice (...) was assessed via spontaneous reports as well as rating scales throughout the study period. In all 3 studies, there was no significant differentiation from placebo on the primary measure (change in HAM-A) for any tiagabine dose (P > 0.05). In the 2 flexible-dose studies, the tiagabine group showed improvements over time in the HAM-A that reached significance only in those patients who completed 10 weeks of treatment (study 2, P = 0.018; study 3, P = 0.036). The most common adverse events were dizziness

2008 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>